D. Moro-Sibilot 1, ⁎ , K. Nakagawa 2, E.B. Garon 3, T. Seto 4, M. Nishio 5, S. Ponce Aix 6, C.H. Chiu 7, K. Park 8, S. Novello 9, E. Nadal 10, F. Imamura 11, K. Yoh 12, J.Y. Shih 13, K. Hung Au 14, S. Enatsu 15, A.H. Zimmermann 16, B. Frimodt-Moller 17, C.M. Visseren Grul 18, M. Reck 19
1 CHU de Grenoble, Grenoble, France
2 Department of medical oncology, Kindai University Faculty of Medicine, Osaka, Japon
3 David Geffen School of Medicine, University of California, Los Angeles, États-Unis
4 National Kyushu Cancer Center, Fukuoka, Japon
5 Department of Thoracic Medical Oncology, The Cancer Institute Hospital of Japanese Foundation for Cancer Research, Tokyo, Japon
6 Hospital 12 de Octubre, Madrid, Espagne
7 Taipei Veterans General Hospital, Taipei, Taïwan, République de Chine
8 Samsung Medical Center, Division of Hematology/Oncology, Sungkyunkwan University School of Medicine, Seoul, République de Corée
9 Department of Oncology, University of Turin, Orbassano, Italie
10 Institut Català d’Oncologia, L’Hospitalet, Barcelona, Espagne
11 Osaka Medical Centre for Cancer and Cardiovascular Diseases, Osaka, Japon
12 National Cancer Centre Hospital East, Kashiwa, Japon
13 Department of Internal Medicine, National Taiwan University Hospital, Taipei, Taïwan, République de Chine
14 Queen Elizabeth Hospital, Kowloon, Hong Kong
15 Lilly Research Laboratories Japan, Kobe-Shi, Japon
16 Eli Lilly & Co, Indianapolis, États-Unis
17 Eli Lilly and Company, Copenhagen, Danemark
18 Lilly Oncology Europe, Utrecht, Pays-Bas
19 LungenClinic, Airway Research Center North (ARCN), German Center for Lung Research (DZL), Grosshansdorf, Allemagne